The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.
Listed below is the senior management team at BioPharmX.
A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as the aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.
"Our mission at BioPharmX is to fulfill the unmet needs of millions of people whose conditions have been overlooked by others."
Mr. Kitchener has over 20 years of broad financial leadership experience in financial planning and analysis, treasury, accounting and investor relations. He has a diverse industry background in financial services, high-technology companies such as Cisco Systems and Synopsys, and with the high-growth medical-technology company, Cepheid, where he served as vice president of finance. Kitchener holds a Master of Business Administration from Cornell University and a Bachelor of Science in mathematics from University of California, Santa Cruz.
"Helping the company make prudent financial decisions that deliver sustainable growth, predictable results, and return high shareholder value is the best sense of achievement."
Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, he was Vice President of Engineering at Demira where he helped develop photodynamic therapies, and directed advanced research at Solta Medical where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
"BioPharmX is driven not only by a desire to explore what is possible through scientific breakthroughs but also by what science can do to satisfy the needs of patients."
Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology, and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation, and served as an independent consultant for a number of pharmaceutical and medical device companies.
“Being a part of a team that brings new technologies to market that change people’s lives is the most exciting way to start each day.”
A seasoned executive with decades of experience in creating license, distribution and other agreements, Ms. Bots will guide BioPharmX Corporation’s licensing and strategic partnerships. During her three-decade career, she has used licensing, partnerships and strategic acquisitions to boost the sales and profitability at several multinationals. As head of the global skincare business of Royal Philips Electronics NV, she oversaw partnership development and acquisitions, managed joint ventures with companies around the world and launched R&D programs resulting in products sold internationally. Earlier, she managed Philips’ Oral Health Care operations in EMEA leading to growth and profitability. Ms. Bots has also served in executive roles where she built, inspired and managed multi-cultural teams at Aon Risk Solutions, Reed/Elsevier, Beam Suntory, Altadis USA and Royal Agio Cigars. She has a degree in Economics from Fontys University of Applied Sciences in Eindhoven, Netherlands, and she has studied at Erasmus University in Rotterdam and Babson College in Boston.
"The right partnership ad licensing agreements can help BioPharmX achieve its potential by enabling the company to more effectively focus its resources on fulfilling unmet medical needs of patients worldwide."
Dr. Herron is a physician scientist with nearly three decades of dermatology experience and maintains an active clinical practice in Palo Alto, California. As faculty at Stanford University School of Medicine he conducted biomedical research, consulted with the biopharmaceutical industry, authored or co-authored more than 30 peer-reviewed papers, and secured several patents in the biomedical field. In addition he held the position of medical director for Reliant Technologies. Dr. Herron has been honored for his work in the field and is repeatedly recognized as a thought-leading physician. He graduated from Lewis and Clark College with degrees in chemistry and biology, completed his doctoral work at Oregon State University in biochemistry and biophysics and obtained his medical doctor degree from University of Southern California Medical School.